Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
193.91
+0.90 (0.47%)
At close: Aug 28, 2025, 4:00 PM
193.90
-0.01 (-0.01%)
After-hours: Aug 28, 2025, 4:31 PM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 16 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $239.88, which forecasts a 23.71% increase in the stock price over the next year. The lowest target is $153 and the highest is $307.
Price Target: $239.88 (+23.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Buy | 6 | 7 | 9 | 9 | 10 | 10 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 16 | 16 | 17 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $254 → $260 | Buy | Maintains | $254 → $260 | +34.08% | Aug 19, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $243 → $290 | Strong Buy | Maintains | $243 → $290 | +49.55% | Aug 8, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $210 → $230 | Buy | Maintains | $210 → $230 | +18.61% | Aug 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $212 → $220 | Buy | Maintains | $212 → $220 | +13.45% | Aug 8, 2025 |
| UBS | UBS | Strong Buy Maintains $306 → $307 | Strong Buy | Maintains | $306 → $307 | +58.32% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
732.25M
from 363.64M
Increased by 101.37%
Revenue Next Year
1.29B
from 732.25M
Increased by 76.17%
EPS This Year
-3.34
from -6.53
EPS Next Year
2.74
from -3.34
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 815.9M | 1.7B | |||
| Avg | 732.3M | 1.3B | |||
| Low | 621.9M | 921.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 124.4% | 129.2% | |||
| Avg | 101.4% | 76.2% | |||
| Low | 71.0% | 25.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.34 | 8.39 | |||
| Avg | -3.34 | 2.74 | |||
| Low | -5.95 | -0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.